DFDA

ACE Inhibitors / ARBs (e.g., Lisinopril)

Treatment for Coronary Artery Disease

Typical Dosage: Lisinopril: 5-40mg daily

Effectiveness
80%
Safety Score
70%
Clinical Trials
800
Participants
500K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Lisinopril: 5-40mg daily
Time to Effect
days-weeks for blood pressure, months-years for cardiovascular protection
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
40(Treat 40 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$150
Side Effect Mgmt:$50
Total Annual:$230
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$10,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$1,150
Comparison vs No Treatment
Cost Difference
+$230/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
ACE Inhibitors / ARBs (e.g., Lisinopril) Outcomes

for Coronary Artery Disease

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+20%
Common Side Effects
Cough (ACE inhibitors)
+8%
Hyperkalemia
+2%
Hypotension
+5%
Angioedema (rare)
+0.1%

Sources:

nih.gov
nih.gov
jacc.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov